mr-x

@Philip
May be you missed:

Despite underwhelming preliminary data from an earlier study, InflaRx (NASDAQ:IFRX) initiates Phase III trial evaluating IFX-1 in severe COVID-19-induced pneumonia, subject to regulatory approval
(SeekingAlpha.com)